Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RomaniaBack to Romania

Clinical trials in Ploiesti – page 4

54 clinical trials in Ploiesti, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Ploiesti at a glance
54
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

54 trials in Ploiesti

Open in trial search

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Not recruiting

A study testing cagrilintide for weight loss in people with overweight or obesity and type 2 diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Type 2 diabetes mellitus

Not recruiting

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S

Type 1 diabetes mellitus

Not recruiting

Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Hormone-refractory prostate cancer

Not recruiting

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Celgene Corp.

Metastatic malignant melanoma

Not recruiting

Study Comparing ABP 206 and Nivolumab for Patients with Unresectable or Metastatic Melanoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Amgen Inc.

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Not recruiting

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:F. Hoffmann-La Roche AG

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Hepatocellular carcinoma+14

Not recruiting

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer stage IV

Not recruiting

Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Romania

The busiest research cities in the country

All 65 cities in Romania

Clinical research in Ploiesti

What the registry says about research in the country

01 Oncology Research

Significant clinical trials focusing on advanced cancer treatments, particularly in lung cancer and prostate cancer therapies. Studies evaluating novel immunotherapy combinations and targeted treatments for enhanced patient outcomes.

  • Non-small cell lung cancer trials
  • Metastatic prostate cancer studies
  • Head and neck cancer research

Multiple investigations of combination therapies and comparative effectiveness studies with established treatments.

02 Gastrointestinal Disorders

Comprehensive research into inflammatory bowel diseases, with particular emphasis on ulcerative colitis and Crohn's disease treatments. Studies evaluating novel therapeutic agents for disease management.

  • Ulcerative colitis treatments
  • Crohn's disease therapies
  • Cholangiocarcinoma research

Focus on developing innovative treatment approaches for chronic gastrointestinal conditions.

03 Metabolic and Cardiovascular Studies

Extensive research into diabetes management and cardiovascular health, including trials for hypertriglyceridemia and heart failure prevention. Studies evaluating new therapeutic approaches for metabolic disorders.

  • Type 2 diabetes treatments
  • Cardiovascular disease prevention
  • Hypertriglyceridemia management

Integration of novel therapeutic agents with established treatments for improved patient outcomes.

Back to RomaniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.